12:00 AM
 | 
Dec 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Acyclovir Lauriad: Final Phase III data

Final data from the double-blind, international Phase III LIP trial in 775 patients with recurrent herpes labialis showed that a single 50 mg dose of acyclovir Lauriad met the primary endpoint of significantly decreasing time to healing of primary vesicular lesions vs. placebo (p=0.043). Acyclovir Lauriad also met several...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >